A randomized double - blind placebo - controlled cross - over trial of the <font color="red">impact_1</font> <font color="red">on_1</font> <font color="red">quality_4</font> <font color="red">of_4</font> <font color="red">life_4</font> of continuing dexamethasone beyond 24   h following adjuvant chemotherapy for breast cancer . 
<br>
<br> Uncertainty remains about the optimal anti - emetic regimen for control of delayed <font color="red">nausea_2</font> <font color="red">and_2</font> <font color="red">vomiting_2</font> after adjuvant chemotherapy for breast cancer . Many patients receive dexamethasone but complain of <font color="red">insomnia_2</font> <font color="red">,_2</font> <font color="red">anxiety_2</font> <font color="red">/_2</font> <font color="red">agitation_2</font> <font color="red">,_2</font> <font color="red">and_1</font> <font color="red">indigestion_2</font> <font color="red">._2</font> The aim was to determine if patients receiving chemotherapy for breast cancer <font color="red">prefer_1</font> treatment with dexamethasone or placebo <font color="red">for_1</font> <font color="red">prophylaxis_1</font> <font color="red">against_1</font> <font color="red">delayed_1</font> <font color="red">nausea_4</font> <font color="red">and_4</font> <font color="red">vomiting_4</font> <font color="red">,_4</font> <font color="red">and_1</font> <font color="red">to_1</font> <font color="red">compare_1</font> <font color="red">quality_4</font> <font color="red">of_4</font> <font color="red">life_4</font> <font color="red">(_4</font> <font color="red">QOL_4</font> <font color="red">)_4</font> <font color="red">between_1</font> <font color="red">the_1</font> <font color="red">two_1</font> <font color="red">treatments_1</font> <font color="red">._1</font> In this randomized , double - blind , cross - over trial , we compared oral dexamethasone ( 4   mg twice daily for 2   days ) versus placebo for chemotherapy - naïve patients with breast cancer . All patients received intravenous granisetron and dexamethasone pre - chemotherapy and oral granisetron on day 2 . <font color="red">Primary_1</font> <font color="red">endpoints_1</font> <font color="red">were_1</font> <font color="red">:_1</font> <font color="red">(_1</font> <font color="red">i_1</font> <font color="red">)_1</font> <font color="red">patient_3</font> <font color="red">preference_3</font> <font color="red">;_3</font> <font color="red">(_2</font> <font color="red">ii_2</font> <font color="red">)_2</font> <font color="red">difference_2</font> <font color="red">between_2</font> <font color="red">cycles_2</font> <font color="red">in_2</font> <font color="red">change_2</font> <font color="red">of_2</font> <font color="red">QOL_4</font> <font color="red">from_1</font> <font color="red">days_1</font> <font color="red">1_1</font> <font color="red">to_1</font> <font color="red">8_1</font> <font color="red">._1</font> Median age of the 94 women was 51   years ( range 27 - 76 ) : 79 received fluorouracil / epirubicin / cyclophosphamide and 15 received doxorubicin / cyclophosphamide . Thirteen withdrew pre - cycle 2 with no differences between arms . Of 80 patients stating a <font color="red">preference_1</font> <font color="red">,_1</font> 31 <font color="red">preferred_1</font> placebo ( 39   % , 95   % CI : 28 - 50   % ) and 37 ( 46   % , 95   % CI : 35 - 58   % ) <font color="red">preferred_1</font> dexamethasone ; 12 had <font color="red">no_1</font> <font color="red">preference_1</font> <font color="red">._1</font> There were no differences in <font color="red">intensity_1</font> <font color="red">of_1</font> <font color="red">vomiting_3</font> <font color="red">,_3</font> <font color="red">nausea_3</font> <font color="red">,_3</font> <font color="red">or_2</font> <font color="red">time_3</font> <font color="red">to_3</font> <font color="red">onset_3</font> <font color="red">of_3</font> <font color="red">vomiting_3</font> <font color="red">._3</font> There was greater decrease in <font color="red">global_1</font> <font color="red">QOL_2</font> ( p   =   0.06 ) when patients received dexamethasone . <font color="red">No_1</font> <font color="red">other_1</font> <font color="red">symptom_2</font> <font color="red">/_2</font> <font color="red">QOL_2</font> <font color="red">domains_1</font> differed significantly . In conclusion , no significant difference was found in <font color="red">patient_1</font> <font color="red">preference_1</font> <font color="red">,_1</font> <font color="red">QOL_2</font> <font color="red">,_2</font> or <font color="red">symptoms_1</font> regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .